225 related articles for article (PubMed ID: 35355169)
21. Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye.
Horwath-Winter J; Bergloeff J; Floegel I; Haller-Schober EM; Schmut O
Br J Ophthalmol; 2003 Jan; 87(1):54-6. PubMed ID: 12488263
[TBL] [Abstract][Full Text] [Related]
22. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
Ababneh OH; Cetinkaya A; Kulwin DR
Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
[TBL] [Abstract][Full Text] [Related]
23. Evaluating the effects of Botulinum Toxin A on tear metrics in patients with hemifacial spasm.
Mali YP; Schultze RL; Wladis EJ
Orbit; 2017 Oct; 36(5):307-310. PubMed ID: 28627956
[TBL] [Abstract][Full Text] [Related]
24. A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques.
Lolekha P; Choolam A; Kulkantrakorn K
Neurol Sci; 2017 Nov; 38(11):2031-2036. PubMed ID: 28884242
[TBL] [Abstract][Full Text] [Related]
25. [Lacrimal film evaluation of patients with facial dystonia during botulinum toxin type A treatment].
Costa PG; Cardoso IP; Saraiva FP; Raiza AC; Tanaka LK; Matayoshi S
Arq Bras Oftalmol; 2006; 69(3):319-22. PubMed ID: 16936952
[TBL] [Abstract][Full Text] [Related]
26. Comparison of two different formulations of botulinum toxin A for the treatment of blepharospasm and hemifacial spasm.
Wu CJ; Shen JH; Chen Y; Lian YJ
Turk Neurosurg; 2011; 21(4):625-9. PubMed ID: 22194126
[TBL] [Abstract][Full Text] [Related]
27. Outcome of Injection Botulinum Toxin in Blepharospasm.
Amatya M; Limbu B; Sthapit PR; Gurung HB; Saiju R
Nepal J Ophthalmol; 2021 Jan; 13(25):40-49. PubMed ID: 33981096
[TBL] [Abstract][Full Text] [Related]
28. Botulinum Toxin A Injection for the Treatment of Intractable Dry Eye Disease.
Choi EW; Yeom DJ; Jang SY
Medicina (Kaunas); 2021 Mar; 57(3):. PubMed ID: 33800125
[No Abstract] [Full Text] [Related]
29. Quality of life in hemifacial spasm patient after treatment with botulinum toxin A; a 24-week, double-blind, randomized, cross-over comparison of Dysport and Neuronox study.
Kongsengdao S; Kritalukkul S
J Med Assoc Thai; 2012 Mar; 95 Suppl 3():S48-54. PubMed ID: 22619887
[TBL] [Abstract][Full Text] [Related]
30. [Essential blepharospasm and hemifacial spasm: characteristic of the patient, botulinum toxin A treatment and literature review].
Schellini SA; Matai O; Igami TZ; Padovani CR; Padovani CP
Arq Bras Oftalmol; 2006; 69(1):23-6. PubMed ID: 16491229
[TBL] [Abstract][Full Text] [Related]
31. Tear osmolarity, dry eye syndrome, blepharospasm and botulinum neurotoxin.
Girard B; de Saint Sauveur G
J Fr Ophtalmol; 2021 Dec; 44(10):1553-1559. PubMed ID: 34756743
[TBL] [Abstract][Full Text] [Related]
32. A Double-Blind, Placebo-Controlled Study of Appropriate Site of Botulinum Toxin Therapy in Hemifacial Spasm.
Jitpimolmard S; Thinkhamrop B; Tiamkao S; Arunpongpaisal S; Arayavichanon P; Kosuwan W; Jitpimolmard S; Sawanyawisuth K
Adv Ther; 2022 May; 39(5):2025-2034. PubMed ID: 35266085
[TBL] [Abstract][Full Text] [Related]
33. Botulinum toxin treatment of hemifacial spasm and blepharospasm: objective response evaluation.
Thussu A; Barman CR; Prabhakar S
Neurol India; 1999 Sep; 47(3):206-9. PubMed ID: 10514580
[TBL] [Abstract][Full Text] [Related]
34. Use of Alleviating Maneuvers for Periocular Facial Dystonias.
Kilduff CL; Casswell EJ; Salam T; Hersh D; Ortiz-Perez S; Ezra D
JAMA Ophthalmol; 2016 Nov; 134(11):1247-1252. PubMed ID: 27606483
[TBL] [Abstract][Full Text] [Related]
35. The changes in corneal astigmatism after botulinum toxin-a injection in patients with blepharospasm.
Moon NJ; Lee HI; Kim JC
J Korean Med Sci; 2006 Feb; 21(1):131-5. PubMed ID: 16479079
[TBL] [Abstract][Full Text] [Related]
36. Effects of the periocular botulinum toxin on the ocular surface and anterior chamber: a prospective study in patients with hemifacial spasm and blepharospasm.
Romero-Caballero MD; Miralles de Imperial-Ollero JA; Sarabia-Marín E; Villegas-Pérez MP
Int Ophthalmol; 2023 Aug; 43(8):2731-2736. PubMed ID: 37185774
[TBL] [Abstract][Full Text] [Related]
37. Topical steroid and non-steroidal anti-inflammatory drugs inhibit inflammatory cytokine expression on the ocular surface in the botulinum toxin B-induced murine dry eye model.
Zhu L; Zhang C; Chuck RS
Mol Vis; 2012; 18():1803-12. PubMed ID: 22815633
[TBL] [Abstract][Full Text] [Related]
38. Correlation of Dry Eye Workshop Dry Eye Severity Grading System With Tear Meniscus Measurement by Optical Coherence Tomography and Tear Osmolarity.
Tukenmez-Dikmen N; Yildiz EH; Imamoglu S; Turan-Vural E; Sevim MS
Eye Contact Lens; 2016 May; 42(3):153-7. PubMed ID: 26067398
[TBL] [Abstract][Full Text] [Related]
39. Botulinum toxin relieves anxiety and depression in patients with hemifacial spasm and blepharospasm.
Dong H; Fan S; Luo Y; Peng B
Neuropsychiatr Dis Treat; 2019; 15():33-36. PubMed ID: 30587995
[TBL] [Abstract][Full Text] [Related]
40. Impact of botulinum toxin-A on corneal curvature assessed with Scheimpflug and Placido systems.
Osaki T; Osaki MH; Osaki TH; Hirai FE; Nallasamy N; Campos M
J Cataract Refract Surg; 2016 May; 42(5):750-8. PubMed ID: 27255252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
